Review of Contemporary Philosophy
ISSN: 1841-5261, e-ISSN: 2471-089X
Vol 22 (1), 2023
pp. 4129 - 4140

Prostate Imaging Modalities: A Review of Current Practices and Future Directions

[1]- Muffrih Mohamad Haresi,[2]- Yahya Ali Mohammed Hakami,[3]-Wael Mohammed Hassan Mujarribi,[4]-Muath Abdullah Abdurahman Alzeer,[5]-Mohammad Abdrabalhabeeb Salm Lahmadi,[6]- Mohammed Abdullah Abdulrahman Alzeer,[7]-Hussain Ahmad Ibrahim Moashy,[8]-Adeeb Ahmed Sayed ,[9]-Abdullah Fahad Alhabshan,[10]-Ahmed Ali Ahmed Humedi,[11]-Khalid Ahmed Essa Khormi ,[12]-Abdulaziz Hussain Saeed ,[13]-Tarek Hussein Binmarwan ,[14]-Ziad Meshal Naif Otaibi,[15]-Naif Abdulmajeed Ali Refaei

[1] Ksa, Ministry Of Health, Jazan Health Cluster
[2] Ksa, Ministry Of Health, Jazan Health Cluster
[3] Ksa, Ministry Of Health, Alsulaimi General Hospital
[4] Ksa, Ministry Of Health, First Health Cluster
[5] Ksa, Ministry Of Health, Riyadh First Health Cluster
[6] Ksa, Ministry Of Health, Alaflaj General Hospital
[7] Ksa, Ministry Of Health, Chest Diseases Hospital
[8] Ksa, Ministry Of Health, Chest Hospital
[9] Ksa, Ministry Of Health, Security Forces Hospital
[10]Ksa, Ministry Of Health, Jazan Health Cluster
[11]Ksa, Ministry Of Health, Alsulaimi General Hospital
[12]Ksa, Ministry Of Health, Aleidabi Phc
[13]Ksa, Ministry Of Health, The First Health Cluster In Riyadh
[14]Ksa, Ministry Of Health, Rumah General Hospital
[15]Ksa, Ministry Of Health, Jazan Health Cluster

Abstract:

Background: The prostate gland plays an essential role in male reproductive health, producing fluid that contributes to semen. However, prostate conditions, including benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer, are common, especially in aging men. Imaging techniques are crucial in diagnosing, staging, and monitoring these conditions. Various modalities such as computed tomography (CT), magnetic resonance imaging (MRI), ultrasonography, and their advanced applications, such as multiparametric MRI, provide detailed insights into prostate pathology. These modalities are invaluable for diagnosing prostate malignancies, assessing local extension, and guiding biopsies.

Aim: This review examines the role of current imaging modalities in evaluating prostate conditions, with a particular focus on the advances in MRI technology, including multiparametric imaging, and their potential for improving diagnostic accuracy. It also discusses the contributions of other modalities like CT, ultrasonography, and emerging techniques in prostate care.

Methods: The review synthesizes information from current literature on various imaging modalities used in prostate evaluation. The role of each technique in diagnosing benign and malignant prostate conditions, particularly prostate cancer, is discussed. The accuracy, limitations, and benefits of CT, MRI, and ultrasonography are compared, along with their relevance to clinical practice.

Results: MRI, especially multiparametric MRI, has shown superior sensitivity and specificity in detecting prostate cancer, even in low-grade cases, reducing unnecessary biopsies. While CT is useful in staging and evaluating metastases, it has limitations in detailing prostate anatomy. Ultrasonography remains a vital tool for biopsy guidance and assessing BPH. Each modality's application is tailored based on patient conditions, such as prostate volume, inflammation, or malignancy suspicion.

Conclusion: MRI stands out as the most advanced imaging modality for prostate evaluation due to its high resolution and ability to distinguish between different types of tissue. However, combining imaging techniques offers a comprehensive approach, enhancing diagnostic accuracy for conditions like BPH, prostatitis, and prostate cancer.

Keywords: Prostate imaging, multiparametric MRI, prostate cancer, CT, ultrasonography, benign prostatic hyperplasia (BPH), prostatitis, diagnostic accuracy.

Received: 10 october 2023 **Revised**: 24 November 2023 **Accepted**: 08 December 2023

Introduction:

The prostate is a walnut-sized gland integral to the male reproductive system, responsible for producing and secreting an alkaline fluid into the ejaculate. This gland comprises both glandular and stromal components, which are prone to enlargement and the development of adenocarcinoma in elderly individuals. In younger patients, infection is a more frequent occurrence. Imaging plays a pivotal role in diagnosing various prostatic conditions, including the early detection of carcinoma. Furthermore, imaging is crucial in facilitating tissue sampling, abscess drainage, managing post-procedure collections, and staging and monitoring malignancies [1]. Anatomically, the prostate is situated within the pelvic cavity, beneath the urinary bladder, encircling the prostatic urethra. The gland is anatomically divided into two lateral lobes (right and left) and a single median lobe. The prostate's apex rests on the urogenital diaphragm, while its base is attached to the bladder neck, and the inferolateral surfaces lie on the levator ani fascia, above the urogenital diaphragm. Histologically, the prostate consists of three distinct zones: the central zone (CZ), the peripheral zone (PZ), and the transition zone (TZ). The CZ accounts for 25% of the prostatic mass and forms the base, while the PZ also represents 25% and surrounds the CZ. The TZ encircles the anterolateral portion of the urethra in a horseshoe-like configuration. Notably, the majority of adenocarcinomas (70%) originate from the PZ, with 20% arising from the TZ and 10% from the CZ. In contrast, prostatitis predominantly affects the CZ, and benign prostatic hyperplasia (BPH) typically causes enlargement of the TZ, resulting in adenoma formation [1].

Plain Films and Radiographic Evaluation

While plain radiographs offer limited value in prostate evaluation, they may occasionally be utilized as part of a skeletal survey for assessing or monitoring metastases. Other imaging modalities, such as bone scans, are employed to evaluate bone metastases, while computed tomography (CT) of the chest, abdomen, and pelvis serves a crucial role in staging prostate cancer. Magnetic resonance imaging (MRI) of the prostate provides high sensitivity and specificity in assessing malignancies and local extension, making it an essential tool in clinical practice. Additionally, CT and MRI are used for the precise placement of radiation seeds in pre-radiotherapy planning [1].

Computed Tomography in Prostate Imaging

CT scanning does not provide high-definition imaging of the prostate or its pathologies. The gland’s anatomy and pathology are not clearly delineated through this modality. On CT scans, the central zone typically presents as hyperdense, with a density range of 40 to 60 Hounsfield Units (HU), while the peripheral zone appears hypodense, with a density range of 10-5 HU.

Benign Prostatic Hyperplasia

Although CT scans are not generally utilized for diagnosing benign prostatic hyperplasia (BPH), the condition may be indicated if the prostate extends above the pubic symphysis in axial imaging. BPH can also be detected via CT when the prostate volume exceeds 30 mL, which can be quantified using coronal reformate images [2].

Prostate Inflammation

In cases of prostatitis, the prostate typically appears diffusely hypodense, accompanied by either symmetric or asymmetric enlargement. Prostatic abscesses are characterized by well-defined hypoattenuating areas, with fluid density typically ranging between -19 and 13 HU, and exhibit peripheral rim enhancement. The progression of prostatitis can be tracked using CT scans, providing an alternative to sonography for monitoring disease development [2].

Prostate Cancer

Prostatic malignancies are identified on CT imaging as contrast-enhancing regions, particularly during the venous phase. These areas may appear either focal or diffuse, typically within the peripheral zone. CT scans play a significant role in assessing the extent of prostatic carcinoma, particularly in evaluating local spread and distant metastasis [1][2].

Magnetic Resonance

Magnetic resonance imaging (MRI) serves as an exceptional modality for prostate evaluation due to its superior contrast resolution. This capability allows MRI to effectively differentiate between various anatomical zones of the prostate and detect any associated abnormalities. For prostate imaging, an MRI is typically performed using a pelvic coil, although the use of an endorectal coil provides enhanced resolution and more detailed information (see Image. Normal Prostate, Magnetic Resonance Image Using Endorectal Coil). Recent advancements, such as multiparametric MRI (mp-MRI), functional MRI, and MRI-guided biopsies, have significantly increased the ability of MRI to detect prostate carcinoma, even in cases of low-grade or low-volume malignancies. Essential MRI sequences for evaluating the prostate include T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), which is accompanied by an apparent diffusion coefficient (ADC), and dynamic intravenous contrast-enhanced imaging. DWI measures the diffusion of water molecules at the cellular level, with ADC providing a qualitative assessment of average water diffusion within a voxel. These imaging techniques are particularly valuable in diagnosing prostate carcinoma and prostatitis, including conditions such as prostatic abscesses [3].

Normal Anatomy

The peripheral zone of the prostate is uniformly hyperintense on T2WI, with the hypointense capsule distinguishing its borders. The transition zone appears heterogeneous, while the seminal vesicles are uniformly hyperintense on T2WI, providing a clear visual reference in MRI imaging.

Benign Prostatic Hyperplasia (BPH)

MRI plays a critical role in delineating the prostate's zonal anatomy, glandular volume, and the volume of each zone. In cases of benign prostatic hyperplasia (BPH), the transition zone (TZ) appears heterogeneous on T2WI. Due to the enlargement of glandular or stromal tissues, the resulting nodules may exhibit variable signal intensities on T2WI. Glandular enlargements appear as bright signals, whereas fibromuscular and stromal tissues are darker on T2WI. The estimation of the stromal-to-glandular ratio is vital for determining appropriate medical therapy. Notably, stromal enlargement in BPH can resemble cancerous lesions in the transition zone because of low T2 signal intensity, diffusion restriction, and contrast enhancement, all of which are similar to prostatic carcinoma. However, stromal hyperplasia typically presents with a well-defined, encapsulated appearance, distinguishing it from malignancy [4][5]. BPH can be classified into seven types based on MRI findings. Type 0 refers to minimal or no zonal enlargement, while types 2 to 7 describe various forms of enlargement, such as retrourethral and pedunculated nodules, as well as ectopic or subtrigonal enlargements. MRI's utility extends beyond diagnosing BPH; it is also crucial in detecting prostate carcinoma in patients with elevated PSA levels who are at higher risk of developing prostate cancer [4].

Prostate Infection

Bacterial prostatitis, which may be acute or chronic, predominantly occurs in the peripheral zone of the prostate. Acute prostatitis appears hyperintense on T2WI, with enhanced contrast uptake, while chronic prostatitis typically shows hypointensity on T2WI with diminished contrast enhancement. Chronic prostatitis also displays substantial diffusion restriction due to inflammatory cell infiltration, which can mimic prostatic carcinoma, though the degree of diffusion restriction in prostatitis is usually less than in carcinoma. Non-necrotic granulomatous prostatitis, similarly, hypointense on T2WI with diffusion restriction, lacks post-contrast enhancement, which distinguishes it from chronic prostatitis. The necrotic regions of granulomatous prostatitis exhibit increased signal intensity on T2WI, and when granulomas extend beyond the prostate, they may be challenging to differentiate from carcinoma [5][6]. Prostatitis can progress to abscess formation, which appears hyperintense on T2WI, hypointense on T1WI, and shows peripheral contrast enhancement. Abscesses also demonstrate diffusion restriction and low ADC values [7].

Prostate Malignancy

Prostate carcinoma is associated with significant morbidity and mortality globally. MRI, particularly mp-MRI, plays a crucial role in detecting prostate cancer and minimizing the need for unnecessary biopsies. Pre-biopsy MRI, along with MRI-guided biopsy, offers superior accuracy over transrectal ultrasound-guided biopsies (TRUS), which are prone to error due to biopsy artifacts. MRI can also identify tumors in areas such as the anterior, lateral, and apex regions of the prostate, which may be missed during standard biopsy procedures. Malignant lesions are generally located in the peripheral zone and are characterized by T2 hypointensity, focal enhancement, and low diffusivity. Ill-defined and hypointense lesions in the peripheral zone are highly suspicious for carcinoma. Although malignancy is less common in the transition zone, irregular, spiculated lesions with T2 hypointensity in this region should raise suspicion for malignancy. MRI is also valuable in detecting metastatic spread that may not be visible on bone scans or CT. Additionally, MRI can evaluate pathological fractures and related complications. The Prostate Imaging Reporting and Data System (PI-RADS), updated in 2015 to version 2, standardizes the classification of clinically significant carcinoma based on mp-MRI findings. This system categorizes lesions from PI-RADS 1, indicating a highly unlikely malignancy, to PI-RADS 5, representing highly likely carcinoma, with intermediate categories based on the lesion's characteristics and size [8][9].

Ultrasonography

Ultrasonography, a widely accessible and essential diagnostic tool, is utilized in prostate evaluation and guided prostatic biopsy. Two primary methods—transabdominal ultrasonography (TAUS) and transrectal ultrasonography (TRUS)—are employed for prostate assessment, with TRUS being preferred for biopsy. During a TAUS procedure, a transducer is positioned above the pubic symphysis, with a fluid-filled urinary bladder acting as an acoustic window to visualize the prostate. Normal prostate measurements generally range from 3.75 to 4.00 × 2.5 to 3.00 × 3.1 to 3.8 cm, with a volume of approximately 20 to 25 cm^3. The prostate volume is calculated using the ellipsoid formula: 0.5236 × height (H) × width (W) × length (L) [10]. However, in obese patients or those in whom bladder filling is not feasible, TAUS is limited, necessitating the use of TRUS. TRUS is particularly vital for cases involving suspected prostatic pathology, elevated prostate-specific antigen (PSA) levels, prostatic inflammation, abscesses, or the follow-up of prostatic cancer, as it allows for a detailed evaluation of the prostate. For TRUS, an 8–10 MHz endorectal transducer is carefully inserted into the rectum. The prostate's volume is determined similarly to TAUS, measuring width, height, and length, and assessing the shape, symmetry, echogenicity, and the integrity of the prostatic capsule. Periprostatic structures, such as seminal vesicles and neurovascular bundles, are also examined for any abnormalities, particularly in suspected cases of prostate carcinoma [11]. Elastography, performed during TRUS, assesses prostate tissue firmness, helping to identify areas with increased rigidity, which might not show abnormal echogenicity on grayscale imaging.

Benign Prostatic Hyperplasia

Ultrasonography, both TAUS and TRUS, plays a critical role in evaluating prostate volume to guide clinical decision-making in cases of benign prostatic hyperplasia (BPH). Prostate volume exceeding 80 cm^3 typically warrants open surgery (adenomectomy), while volumes below this threshold often indicate transurethral resection as the preferred management approach. The European Association of Urology (EAU) recommends assessing prostate volume through TRUS and measuring post-void urinary bladder volume via TAUS. Additionally, ultrasound should incorporate the visualization of the upper urinary tract to determine the extent of urinary tract dilatation.

Prostate Inflammation

Prostatitis, often diagnosed clinically, frequently demonstrates an enlarged or deformed gland with an inhomogeneous echotexture on sonography. Acute prostatitis may lead to parenchymal abscesses, appearing as hypoechoic or fluid-filled lesions within the prostate parenchyma. Ultrasound not only aids in diagnosing prostatitis but also serves as a guide for procedures, such as abscess evacuation under ultrasound guidance. Moreover, in chronic prostatitis, ultrasound can be used to guide intraprostatic antibiotic injections, particularly when exacerbating pain is present [12].

Prostatic Neoplasm

Prostate malignancy presents a diagnostic challenge with ultrasonography, as tumors are often isoechoic to surrounding normal tissue or may appear hypoechoic. The use of color Doppler or power Doppler ultrasound helps identify angiogenesis by detecting dilated, tortuous vessels, but it cannot discern small tumor foci. Consequently, ultrasound's diagnostic value for prostatic cancer is approximately 30% to 40% [11]. As such, ultrasound is primarily employed as a guidance tool for prostatic biopsy, particularly in cases where PSA levels are elevated, improving cancer detection. Furthermore, ultrasound is instrumental in assessing local tumor spread and staging the cancer. Recent advancements, such as elastography, have improved the detection of prostate neoplasms by distinguishing differences in tissue consistency. On elastography, cancerous tissue appears firmer than surrounding normal tissue. Three-dimensional TRUS enables the computer processing of sectional prostate images, providing additional detail about the morphology and surrounding structures [11]. Contrast-enhanced ultrasound, with its high sensitivity, is particularly useful for distinguishing neoplastic tissue from normal prostate tissue and is invaluable during ultrasound-guided biopsies [14].

Nuclear Medicine

Nuclear medicine plays a pivotal role in the diagnosis, staging, re-staging, and therapeutic management of prostate carcinoma. One of the key applications of nuclear medicine is in the identification of skeletal metastases, which can be detected through bone scans. Positron emission tomography (PET) is another crucial imaging technique employed to assess malignant activity and its dissemination throughout the body. Notably, the choline derivative radiotracer, 18F-fluorocholine (F-FCH), is currently the most commonly used radiotracer for diagnosing prostate carcinoma. When PET is integrated with computed tomography (CT) or magnetic resonance imaging (MRI), forming PET/CT or PET/MRI scans, it provides invaluable metabolic and functional data derived from PET that complement the anatomical information obtained from CT or MRI [15][16]. Additionally, prostate-specific membrane antigen (PSMA) is a marker expressed on the surface of prostate cancer cells, as well as in nodal and bone metastases. The use of Ga-labeled PSMA inhibitors as a PET tracer has gained increasing popularity due to its dual role in both the diagnosis and therapy of prostate carcinoma [16].

Angiography

Angiography is employed in the management of benign prostatic hyperplasia (BPH) and related bleeding through a technique known as prostatic artery embolization. This interventional procedure is specifically used to treat patients experiencing lower urinary tract symptoms due to BPH. Prostatic artery embolization has proven effective in alleviating these symptoms, offering a valuable therapeutic approach for individuals with BPH and associated complications.

Clinical Significance

Prostate imaging plays a crucial role in the detection and evaluation of various prostatic pathologies, including infections, glandular enlargement, and carcinoma. It is especially important in the staging of prostate cancer, as accurate staging is critical for determining appropriate treatment strategies. The Prostate Imaging Reporting and Data System (PI-RADS) provides a standardized classification based on MRI findings, which assists clinicians in guiding management decisions. Additionally, imaging modalities such as ultrasound (US) and MRI, both of which are often used for diagnostic and therapeutic procedures, are integral in the comprehensive management of prostate diseases. These imaging techniques help in assessing the extent of the disease and in planning targeted interventions.

Other Imaging Modalities:

Other Advanced Imaging Modalities in Prostate Imaging

In addition to the conventional imaging techniques such as ultrasound (US) and magnetic resonance imaging (MRI), several other advanced imaging modalities have emerged in recent years, significantly enhancing the diagnostic and therapeutic management of prostate conditions, particularly prostate carcinoma. These modalities offer unique benefits, providing detailed anatomical, functional, and metabolic insights that improve the accuracy of diagnosis, staging, and treatment planning. These advanced imaging techniques include multi-parametric MRI, dynamic contrast-enhanced MRI, functional MRI, diffusion-weighted imaging (DWI), and advanced positron emission tomography (PET) techniques.

1. Multi-Parametric MRI (mpMRI)

Multi-parametric MRI (mpMRI) is an advanced imaging modality that combines several MRI sequences, including T2-weighted imaging (T2WI), diffusion-weighted imaging (DWI), dynamic contrast-enhanced MRI (DCE-MRI), and magnetic resonance spectroscopy (MRS). mpMRI has become the gold standard for non-invasive prostate cancer detection, localization, and staging. The combination of these sequences offers a comprehensive evaluation of prostate pathology, allowing clinicians to assess tumor location, size, and extent. T2WI provides high-resolution anatomical images that help in visualizing the prostate gland and detecting anatomical abnormalities, such as lesions. DWI, which assesses the diffusion of water molecules within tissues, is particularly useful in detecting areas of restricted diffusion that often correspond to malignant tumors. DCE-MRI helps to evaluate the perfusion of tissues and identifies regions with abnormal blood flow, which can be indicative of tumor activity. MRS, though less commonly used, measures metabolic changes within the prostate tissue, further of suspected prostate cancer. It is increasingly used for targeted biopsies, where areas of interest identified by mpMRI are biopsied with greater precision, improving the detection rates of clinically significant cancers while reducing unnecessary biopsies of benign lesions. Additionally, mpMRI is valuable for assessing prostate cancer staging, particularly in determining extracapsular extension (ECE) and lymph node involvement, crucial for treatment planning. The advent of mpMRI has led to improved detection, more accurate staging, and better management decisions for patients with prostate cancer.

2. Dynamic Contrast-Enhanced MRI (DCE-MRI)

Dynamic contrast-enhanced MRI (DCE-MRI) is an advanced imaging technique that assesses the vascular characteristics of prostate tissue by tracking the flow of a contrast agent through the tissue. The technique is particularly valuable for identifying malignancies in the prostate, as tumors typically exhibit increased blood flow and abnormal vascular patterns compared to normal tissue. During DCE-MRI, a contrast agent is injected, and rapid imaging is performed over several minutes to monitor the contrast's uptake and washout in the prostate. Tumors often show rapid enhancement followed by early washout, distinguishing them from benign tissue, which typically exhibits slower, more prolonged enhancement. DCE-MRI is an important tool for evaluating the aggressiveness of prostate cancer, providing critical information for staging and treatment planning. It is also useful in monitoring the response of prostate tumors to therapies such as radiation or hormone treatment.

3. Diffusion-Weighted Imaging (DWI)

Diffusion-weighted imaging (DWI) is an MRI technique that measures the movement of water molecules within tissues. The degree of diffusion is influenced by the cellular density of tissues: malignant tissues tend to have a higher cellular density, which restricts water movement, leading to a reduction in the apparent diffusion coefficient (ADC). In contrast, normal prostate tissue and benign lesions have higher water mobility. DWI is particularly useful in identifying prostate cancer, as tumors typically show restricted diffusion. This can be quantified using the ADC value, with lower ADC values correlating with more aggressive malignancies. DWI is non-invasive and provides functional information about tissue characteristics, aiding in the detection and characterization of prostate cancer. It is often used in conjunction with T2-weighted imaging and DCE-MRI as part of mpMRI to enhance diagnostic accuracy and guide biopsy procedures.

4. Positron Emission Tomography (PET) and PET/CT Imaging

Positron emission tomography (PET) has emerged as a valuable imaging technique in the diagnosis and management of prostate cancer. PET scans detect metabolic activity within tissues by measuring the distribution of radiotracers, which are injected into the bloodstream and taken up by areas of high metabolic activity. The most commonly used radiotracer for prostate cancer imaging is 18F-fluorodeoxyglucose (18F-FDG), which highlights areas of high glucose metabolism, commonly associated with malignancies. However, the use of 18F-FDG in prostate cancer is limited due to its low sensitivity for detecting early-stage prostate cancer, as prostate tumors often do not exhibit significant glucose uptake in the early stages. To overcome these limitations, newer PET tracers have been developed, such as 18F-fluorocholine (18F-FCH), which targets prostate-specific membrane antigen (PSMA) overexpressed in prostate cancer cells. PET scans using 18F-FCH have demonstrated superior sensitivity in detecting prostate cancer compared to conventional imaging methods. Moreover, the combination of PET with computed tomography (CT) (PET/CT) or MRI (PET/MRI) allows for enhanced anatomical localization of metabolic activity, facilitating better tumor detection, staging, and treatment planning. These hybrid imaging modalities combine the functional imaging capabilities of PET with the detailed anatomical information provided by CT or MRI, significantly improving the accuracy of prostate cancer detection, particularly in patients with biochemical recurrence or advanced disease.

5. Prostate-Specific Membrane Antigen (PSMA) PET Imaging

A significant advancement in prostate cancer imaging is the development of prostate-specific membrane antigen (PSMA) PET imaging. PSMA is a cell surface protein highly expressed on prostate cancer cells, particularly in advanced stages, making it an excellent target for imaging and therapy. Radiotracers targeting PSMA, such as 68Ga-PSMA, allow for highly sensitive imaging of prostate cancer, even in early or low-volume disease. PSMA PET imaging has proven to be particularly valuable in detecting recurrent prostate cancer, especially in patients with rising PSA levels after initial treatment. It provides superior detection of lymph node and distant metastases compared to conventional imaging methods, which is crucial for accurate staging and treatment planning. PSMA PET also holds promise for theranostic applications, where the same radiotracer used for imaging is also employed for targeted therapy, such as PSMA-targeted radiotherapy.

6. Elastography

Elastography is a novel imaging technique that assesses the stiffness of tissue, which can be particularly useful in prostate imaging. In prostate cancer, malignant tissue tends to be stiffer than normal or benign tissue due to increased fibrosis and cellular density. Elastography measures tissue stiffness either through ultrasound or MRI, with the latter referred to as magnetic resonance elastography (MRE). Using elastography during imaging provides a quantitative assessment of tissue stiffness, with higher stiffness values typically correlating with cancerous lesions. In prostate cancer, elastography can aid in identifying suspicious areas for biopsy and assist in the monitoring of disease progression. This technique is increasingly integrated into other imaging modalities such as TRUS (transrectal ultrasound) and mpMRI to enhance diagnostic accuracy and guide treatment decisions.

7. 3D Ultrasound and Fusion Imaging

Three-dimensional (3D) ultrasound imaging and fusion imaging are emerging techniques that offer advanced visualization capabilities in prostate imaging. 3D ultrasound allows for the reconstruction of prostate images from multiple 2D slices, providing a more comprehensive view of the prostate and its lesions. This enhances the ability to assess tumor location and volume, which is crucial for guiding biopsy procedures and planning surgery. Additionally, fusion imaging combines real-time ultrasound with pre-acquired images from MRI or CT scans, allowing for the accurate overlay of the anatomical details from MRI or CT with real-time ultrasound during biopsy or treatment. Fusion imaging improves the precision of prostate cancer diagnosis and intervention, leading to better outcomes in terms of cancer detection and treatment accuracy. The advent of advanced imaging techniques, including multi-parametric MRI, PET/CT, PSMA PET, and elastography, has significantly transformed the approach to prostate cancer diagnosis, staging, and treatment. These modalities offer complementary capabilities, providing both functional and anatomical insights into prostate pathology that were previously difficult to obtain through conventional imaging. Their integration into clinical practice has improved diagnostic accuracy, allowed for more precise treatment planning, and enhanced the ability to monitor disease progression or response to therapy. The future of prostate imaging lies in the continued development of these advanced technologies, which promise to further refine the management of prostate cancer and improve patient outcomes.

Case Studies:

This Magnetic Resonance Imaging (MRI) of the prostate is classified using the Imaging Reporting and Data System (PI-RADS) version 2. The image consists of multiple imaging planes: (A) Sagittal T2, (B) Coronal T2, (C) Axial T2, (D) Diffusion-weighted Imaging (DWI), and (E) Apparent Diffusion Coefficient (ADC). The sagittal, coronal, and axial T2 images provide detailed anatomical views of the prostate, showcasing the location and structure of the lesion. The lesion is located in the peripheral zone of the prostate, an area often associated with malignancy. On Diffusion-weighted Imaging (DWI), the lesion appears with faint hyperintensity, suggesting restricted diffusion, which is often a characteristic of malignancy due to the higher cellularity of tumors. On the Apparent Diffusion Coefficient (ADC) image, there is faint suppression of the lesion, further indicating restricted diffusion. This restricted diffusion is typical of malignant lesions, which present reduced water molecule movement compared to normal tissue. The ill-defined nature of the lesion suggests that it may not have well-demarcated borders, which is common in prostate cancers. The combination of imaging findings, particularly the hyperintensity on DWI and suppression on ADC, raises concern for a potential malignancy, aligning with the clinical considerations in the PI-RADS-2 classification. Further clinical correlation and biopsy may be necessary to confirm the diagnosis [17].



Figure 1: Magnetic Resonance Image of Prostate, Imaging Reporting and Data System-2 Classification.

This Magnetic Resonance Imaging (MRI) of the prostate is classified using the Imaging Reporting and Data System (PI-RADS) version 3. The image includes three key sequences: (A) Axial T2, (B) Diffusion-weighted Imaging (DWI), and (C) Apparent Diffusion Coefficient (ADC). On the Axial T2 image, a focal area of hypointensity is identified in the prostate, indicating a potential abnormality. Hypointensity on T2-weighted imaging can suggest the presence of a lesion, often linked to malignancy. The Diffusion-weighted Imaging (DWI) sequence shows faint diffusion restriction within the same focal area, as indicated by an orange arrow. This restricted diffusion is a feature that may indicate a higher cellularity or a less mobile water environment, characteristics commonly associated with malignancies. The Apparent Diffusion Coefficient (ADC) map further confirms this, showing the restricted diffusion as a faint signal decrease, which is consistent with malignancy, as these lesions typically demonstrate low ADC values. The findings in all three imaging planes—T2 hypointensity, faint diffusion restriction on DWI, and ADC suppression—align with the characteristics of a lesion that may be suspicious for cancer. Given the PI-RADS 3 classification, this lesion is likely to be of intermediate likelihood of malignancy, and further diagnostic evaluation, such as biopsy, may be necessary to confirm the nature of the lesion [17].



Figure 2: Magnetic Resonance Image of Prostate, Imaging Reporting and Data System 3 Classification.

This image displays a normal prostate assessed using Magnetic Resonance Imaging (MRI) with an endorectal coil, which is positioned in the rectum (visible as a black coil). The image includes several sequences to provide detailed visualization of the prostate tissue: (A) Coronal T2, (B) Axial T2, (C) Diffusion-weighted imaging (DWI), and (D) Apparent Diffusion Coefficient (ADC). In the Coronal and Axial T2-weighted images (A and B), the prostate appears with typical characteristics of normal anatomy, displaying uniform signal intensity throughout the gland. The tissue is homogeneously bright with well-defined borders, which is characteristic of a healthy prostate. The Diffusion-weighted image (C) demonstrates no signs of restricted diffusion, which would indicate any abnormality such as a lesion or cancer. In this case, the diffusion appears unrestricted, which is a common feature of normal prostate tissue, where water molecules are able to diffuse freely. The Apparent Diffusion Coefficient map (D) further supports this finding, showing a typical ADC pattern for healthy tissue with normal ADC values. There is no evidence of low ADC, which would be suggestive of malignancy or high cellularity. This combination of normal T2 signal, unrestricted diffusion on DWI, and appropriate ADC values all indicate that the prostate in this MRI scan is normal, with no signs of pathological changes [17].

Conclusion:

Prostate imaging has evolved significantly, especially with advancements in MRI technology. MRI, particularly multiparametric MRI, is now considered the gold standard for prostate evaluation, offering unmatched accuracy in detecting and staging prostate carcinoma. The use of different imaging techniques has broadened the scope of diagnosis and treatment in prostate health, with MRI providing exceptional contrast resolution that enhances the identification of prostate abnormalities. This modality is especially crucial in diagnosing low-grade or low-volume cancers that are often missed in other imaging methods, thereby reducing the need for unnecessary biopsies. Computed tomography (CT), while not ideal for routine prostate evaluation, remains valuable for staging prostate cancer and detecting distant metastases. Its role is further emphasized in evaluating the extent of prostatic malignancies, especially in more advanced stages. Despite its limitations in detail, CT provides essential information for assessing prostate cancer's local spread and regional involvement. However, its lack of high-definition imaging for prostate-specific pathology restricts its use compared to MRI. Ultrasonography continues to be an important, widely accessible tool, particularly in the guidance of biopsies. Transrectal ultrasonography (TRUS) is the preferred method for guiding prostate biopsies, offering real-time assessment of tissue samples and increasing diagnostic precision. Additionally, ultrasonography plays a significant role in monitoring benign prostatic hyperplasia (BPH) and prostatitis, helping determine prostate volume and guide therapeutic interventions, such as abscess drainage or biopsies. In prostate malignancy, MRI has taken precedence due to its ability to detect cancers in regions of the prostate that may be difficult to biopsy, such as the anterior or apex zones. The introduction of the Prostate Imaging Reporting and Data System (PI-RADS) further standardized the reporting of prostate MRI findings, improving clinical decision-making. Combining these imaging modalities—each with its unique strengths—provides a comprehensive approach to diagnosing and managing prostate conditions. As imaging technology continues to improve, particularly with the advent of functional MRI and advanced ultrasound techniques, the ability to detect, treat, and monitor prostate conditions will undoubtedly continue to improve, leading to better patient outcomes and more precise therapeutic interventions.



Figure 3: Normal Prostate, Magnetic Resonance Image Using Endorectal Coil.

References:

[1] Thornhill BA, Morehouse HT, Coleman P, Hoffman-Tretin JC. Prostatic abscess: CT and sonographic findings. AJR Am J Roentgenol. 1987 May;148(5):899-900.

[2] Jia JB, Houshyar R, Verma S, Uchio E, Lall C. Prostate cancer on computed tomography: A direct comparison with multi-parametric magnetic resonance imaging and tissue pathology. Eur J Radiol. 2016 Jan;85(1):261-267.

[3] Stabile A, Giganti F, Emberton M, Moore CM. MRI in prostate cancer diagnosis: do we need to add standard sampling? A review of the last 5 years. Prostate Cancer Prostatic Dis. 2018 Nov;21(4):473-487.

[4] Guneyli S, Ward E, Thomas S, Yousuf AN, Trilisky I, Peng Y, Antic T, Oto A. Magnetic resonance imaging of benign prostatic hyperplasia. Diagn Interv Radiol. 2016 May-Jun;22(3):215-9.

[5] Kitzing YX, Prando A, Varol C, Karczmar GS, Maclean F, Oto A. Benign Conditions That Mimic Prostate Carcinoma: MR Imaging Features with Histopathologic Correlation. Radiographics. 2016 Jan-Feb;36(1):162-75.

[6] Bour L, Schull A, Delongchamps NB, Beuvon F, Muradyan N, Legmann P, Cornud F. Multiparametric MRI features of granulomatous prostatitis and tubercular prostate abscess. Diagn Interv Imaging. 2013 Jan;94(1):84-90.

[7] Singh P, Yadav MK, Singh SK, Lal A, Khandelwal N. Case series: Diffusion weighted MRI appearance in prostatic abscess. Indian J Radiol Imaging. 2011 Jan;21(1):46-8.

[8] Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, Briganti A, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM., PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. N Engl J Med. 2018 May 10;378(19):1767-1777.

[9] van der Leest M, Israël B, Cornel EB, Zámecnik P, Schoots IG, van der Lelij H, Padhani AR, Rovers M, van Oort I, Sedelaar M, Hulsbergen-van de Kaa C, Hannink G, Veltman J, Barentsz J. High Diagnostic Performance of Short Magnetic Resonance Imaging Protocols for Prostate Cancer Detection in Biopsy-naïve Men: The Next Step in Magnetic Resonance Imaging Accessibility. Eur Urol. 2019 Nov;76(5):574-581.

[10] Guideline developed in collaboration with the American College of Radiology; Society of Radiologists in Ultrasound. AIUM Practice Guideline for the Performance of an Ultrasound Evaluation of the Prostate (and Surrounding Structures). J Ultrasound Med. 2015 Aug;34(8):1-6.

[11] Tyloch JF, Wieczorek AP. The standards of an ultrasound examination of the prostate gland. Part 1. J Ultrason. 2016 Dec;16(67):378-390.

[12] Tyloch JF, Wieczorek AP. The standards of an ultrasound examination of the prostate gland. Part 2. J Ultrason. 2017 Mar;17(68):43-58.

[13] Stamatiou K, Alevizos A, Karanasiou V, Mariolis A, Mihas C, Papathanasiou M, Bovis K, Sofras F. Impact of additional sampling in the TRUS-guided biopsy for the diagnosis of prostate cancer. Urol Int. 2007;78(4):313-7.

[14] Taymoorian K, Thomas A, Slowinski T, Khiabanchian M, Stephan C, Lein M, Deger S, Lenk S, Loening SA, Fischer T. Transrectal broadband-Doppler sonography with intravenous contrast medium administration for prostate imaging and biopsy in men with an elevated PSA value and previous negative biopsies. Anticancer Res. 2007 Nov-Dec;27(6C):4315-20.

[15] Anand SS, Singh H, Dash AK. Clinical Applications of PET and PET-CT. Med J Armed Forces India. 2009 Oct;65(4):353-8.

[16] Cuccurullo V, Di Stasio GD, Mansi L. Nuclear Medicine in Prostate Cancer: A New Era for Radiotracers. World J Nucl Med. 2018 Apr-Jun;17(2):70-78.

[17] Banker, H., & Selvarajan, S. K. (2023). Prostate Imaging. In *StatPearls [Internet]*. StatPearls Publishing.

تقنيات التصوير البروستاتا: مراجعة للممارسات الحالية والاتجاهات المستقبلية

الملخص:

الخلفية: تلعب غدة البروستاتا دورًا أساسيًا في صحة الإنجاب لدى الرجال، حيث تنتج سائلًا يساهم في السائل المنوي. ومع ذلك، فإن حالات البروستاتا، بما في ذلك تضخم البروستاتا الحميد(BPH) ، والتهاب البروستاتا، وسرطان البروستاتا، شائعة، خاصة بين الرجال كبار السن. تعتبر تقنيات التصوير أمرًا بالغ الأهمية في تشخيص هذه الحالات وتصنيفها ومراقبتها. تقدم تقنيات التصوير المختلفة مثل التصوير المقطعي المحوسب(CT) ، التصوير بالرنين المغناطيسي(MRI) ، والأشعة فوق الصوتية، وتطبيقاتها المتقدمة مثل التصوير بالرنين المغناطيسي متعدد المعايير، رؤى تفصيلية حول أمراض البروستاتا. وتعد هذه التقنيات لا غنى عنها لتشخيص الأورام الخبيثة في البروستاتا، وتقييم الامتداد المحلي، وإرشاد الخزعات.

الهدف: تهدف هذه المراجعة إلى استكشاف دور تقنيات التصوير الحالية في تقييم حالات البروستاتا، مع التركيز بشكل خاص على التقدم في تكنولوجيا التصوير بالرنين المغناطيسي، بما في ذلك التصوير متعدد المعايير، وإمكاناتها في تحسين دقة التشخيص. كما تناقش المساهمات التي تقدمها تقنيات أخرى مثل التصوير المقطعي المحوسب، والأشعة فوق الصوتية، والتقنيات الناشئة في رعاية البروستاتا.

الطرق: تقوم المراجعة بتلخيص المعلومات من الأدبيات الحالية حول تقنيات التصوير المختلفة المستخدمة في تقييم البروستاتا. يتم مناقشة دور كل تقنية في تشخيص حالات البروستاتا الحميدة والخبيثة، خاصة سرطان البروستاتا. كما تتم مقارنة دقة وقيود وفوائد التصوير المقطعي المحوسب، والتصوير بالرنين المغناطيسي، والأشعة فوق الصوتية، مع مناقشة صلتها بالممارسة السريرية.

النتائج: أظهر التصوير بالرنين المغناطيسي، وخاصة التصوير بالرنين المغناطيسي متعدد المعايير، حساسية وخصوصية فائقة في اكتشاف سرطان البروستاتا، حتى في الحالات منخفضة الدرجة، مما يقلل من الخزعات غير الضرورية. بينما يعتبر التصوير المقطعي المحوسب مفيدًا في تصنيف المرضى وتقييم النقائل، إلا أنه له حدود في تفصيل تشريح البروستاتا. لا تزال الأشعة فوق الصوتية أداة أساسية في إرشاد الخزعات وتقييم تضخم البروستاتا الحميد. يتم تخصيص تطبيق كل تقنية بناءً على حالة المريض، مثل حجم البروستاتا، أو الالتهاب، أو الشك في الأورام الخبيثة.

الخلاصة: يبرز التصوير بالرنين المغناطيسي كأحدث تقنيات التصوير لتقييم البروستاتا بفضل دقته العالية وقدرته على التمييز بين أنواع الأنسجة المختلفة. ومع ذلك، فإن دمج تقنيات التصوير يقدم نهجًا شاملاً، مما يعزز دقة التشخيص لحالات مثل تضخم البروستاتا الحميد، والتهاب البروستاتا، وسرطان البروستاتا.

الكلمات المفتاحية: تصوير البروستاتا، التصوير بالرنين المغناطيسي متعدد المعايير، سرطان البروستاتا، التصوير المقطعي المحوسب، الأشعة فوق الصوتية، تضخم البروستاتا الحميد(BPH) ، التهاب البروستاتا، دقة التشخيص.